To all our Supporters, Friends and Colleagues and especially to the Patients and Caregivers we serve and to the Healthcare Workers who tirelessly work on behalf of all of us! First of all, I want to take this opportunity to mark the passing of a momentous year and wish everyone a much better 2021. It […]
Hi guys! One of my most favorite things to do under my leadership of the EndBrainCancer Initiative is to talk directly to patients with brain cancer and to hear first hand, “their story” and to “see” with my own eyes as well as to “hear” with my own ears how they IMPACT others simply by […]
Today, May 31, 2020, the very last day of #BTAM month, I find myself reflecting on many things and just looked through the photos from last year’s Bellingham Brain Cancer WALK (BBCW) , Presenting Sponsor: Novocure (www.novocure.com) and am smiling and crying at the same time. Just look at these photos! What a super cool […]
Today, it is May 17, 2020 and I am spending my day reflecting on the national brain tumor community. Specifically, I am also spending a lot of time over the last several weeks, amongst COVID-19, reflecting on the my late husband’s brain cancer journey and the last 18 years of co-founding and running the Chris […]
WEBINAR! COVID-19 & BRAIN CANCER! Important information on how COVID-19 affects Brain Cancer (and other cancer) patients. Join Al Musella of the Musella Foundation and Dr. Eric T. Wong, Brain Tumor Center & Neuro-Oncology Unit, Beth Israel Deaconess Medical Center, Dana Farber/Harvard Cancer Center and Harvard Medical School.
Book Launches with Call for Stories: Author and Advocate Dellann Elliott Mydland Calls for Stories Where Tragedy was Transformed for Good to Help Others SEATTLE, Aug. 27, 2019 /PRNewswire/ — Dellann Elliott Mydland, co-founder of the EndBrainCancer Initiative (EBCI), announces a new book she is writing to tell her story, and invites members of the […]
Another Advocacy Win for Patients: Medicare Finalizes Coverage for Some CAR T-Cell Therapies On August 7, the Centers for Medicare & Medicaid Services (CMS) finalized the decision to cover FDA-approved Chimeric Antigen Receptor T-cell, or “CAR T-cell” therapy, which is a form of cancer treatment that uses a patient’s own genetically-modified immune cells to fight […]
